Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation

Seventy-four patients who relapsed after allogeneic stem cell transplantation were enrolled in a phase IIA study and treated with the sequential infusion of donor lymphocyte infusion (DLI) followed by cytokine-induced killer (CIK) cells. Seventy-three patients were available for the intention to tre...

Full description

Saved in:
Bibliographic Details
Published in:Biology of blood and marrow transplantation 2017-12, Vol.23 (12), p.2070-2078
Main Authors: Introna, Martino, Lussana, Federico, Algarotti, Alessandra, Gotti, Elisa, Valgardsdottir, Rut, Micò, Caterina, Grassi, Anna, Pavoni, Chiara, Ferrari, Maria Luisa, Delaini, Federica, Todisco, Elisabetta, Cavattoni, Irene, Deola, Sara, Biagi, Ettore, Balduzzi, Adriana, Rovelli, Attilio, Parma, Matteo, Napolitano, Sara, Sgroi, Giusy, Marrocco, Emanuela, Perseghin, Paolo, Belotti, Daniela, Cabiati, Benedetta, Gaipa, Giuseppe, Golay, Josée, Biondi, Andrea, Rambaldi, Alessandro
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Seventy-four patients who relapsed after allogeneic stem cell transplantation were enrolled in a phase IIA study and treated with the sequential infusion of donor lymphocyte infusion (DLI) followed by cytokine-induced killer (CIK) cells. Seventy-three patients were available for the intention to treat analysis. At least 1 infusion of CIK cells was given to 59 patients, whereas 43 patients received the complete cell therapy planned (58%). Overall, 12 patients (16%) developed acute graft-versus-host disease (aGVHD) of grades I to II in 7 cases and grades III to IV in 5). In 8 of 12 cases, aGVHD developed during DLI treatment, leading to interruption of the cellular program in 3 patients, whereas in the remaining 5 cases aGVHD was controlled by steroids treatment, thus allowing the subsequent planned administration of CIK cells. Chronic GVHD (cGVHD) was observed in 11 patients (15%). A complete response was observed in 19 (26%), partial response in 3 (4%), stable disease in 8 (11%), early death in 2 (3%), and disease progression in 41 (56%). At 1 and 3 years, rates of progression-free survival were 31% and 29%, whereas rates of overall survival were 51% and 40%, respectively. By multivariate analysis, the type of relapse, the presence of cGVHD, and a short (
ISSN:1083-8791
1523-6536
DOI:10.1016/j.bbmt.2017.07.005